The use of novel psychoactive substances (NPS) is a growing phenomenon worldwide that harms user’s health and increases healthcare system costs. In September 2017, amphetamine-analog benzofurans (APB) were reported by the Sistema de Alertas Tempranas, a brach of Observatorio de Drogas de Colombia. At first, benzofurans use was globally reported as an adulterant of other psychoactive substances but, due its legal status, its easy commercialization and because of government and doctors did not know those substances; they have noticeably been growing as a drug of choice. In the face of this new threat, this review tries to expose information expecting it will help in these needs. A wide bibliographical review was made regarding pharmacodynamic and pharmacokinetic characteristics, clinical effects and toxicity, and marketing strategies about 4-APB, 5-APB and 6-APB.